Please try another search
For the six months ended 30 June 2018, Realm Therapeutics PLC revenues decreased from $619K to $0K. Net loss increased from $3.9M to $10.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development expenses increase from $3M to $7.4M (expense), General and administrative expenses increase from $1.6M to $3.5M (expense).
Period Ending: | Jun 30, 2018 | Dec 31, 2017 | Jun 30, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Total Revenue | 0 | 0.5 | 0.62 | 0.51 |
Gross Profit | 0 | 0.5 | 0.62 | 0.43 |
Operating Income | -10.89 | -6.74 | -3.95 | -4.55 |
Net Income | -10.65 | -6.59 | -3.93 | 1.21 |
Period Ending: | Jun 30, 2018 | Dec 31, 2017 | Jun 30, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Total Assets | 26.73 | 35.11 | 16.65 | 22.25 |
Total Liabilities | 2.45 | 2.91 | 1.39 | 3.2 |
Total Equity | 24.28 | 32.2 | 15.27 | 19.05 |
Period Ending: | Jun 30, 2018 | Dec 31, 2017 | Jun 30, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Period Length: | 6 Months | 12 Months | 6 Months | 12 Months |
Cash From Operating Activities | -10.12 | -9.5 | -5.77 | -4.94 |
Cash From Investing Activities | 16.85 | -25.63 | -0.11 | 10.95 |
Cash From Financing Activities | 0 | 23.23 | 0 | 0.01 |
Net Change in Cash | 6.73 | -11.92 | -5.87 | 5.97 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review